Reply to Kremer M et al., the JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
作者信息
Ohyashiki K, Ohyashiki J H
出版信息
Leukemia. 2006 Jul;20(7):1297-8. doi: 10.1038/sj.leu.2404232. Epub 2006 Apr 13.
PMID:16617315
Abstract
摘要
相似文献
1
Reply to Kremer M et al., the JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.对克雷默·M等人的回复：JAK2 V617F突变在骨髓增生异常/骨髓增殖性疾病中频繁出现，但在伴有纤维化的真性骨髓增生异常综合征中不存在。
Leukemia. 2006 Jul;20(7):1297-8. doi: 10.1038/sj.leu.2404232. Epub 2006 Apr 13.
2
The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.JAK2 V617F突变在骨髓增生异常/骨髓增殖性疾病中频繁出现，但在伴有纤维化的真性骨髓增生异常综合征中不存在。
Leukemia. 2006 Jul;20(7):1315-6. doi: 10.1038/sj.leu.2404231. Epub 2006 Apr 13.
3
The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis.JAK2 V617F突变与伴有或不伴有骨髓纤维化的骨髓增生异常综合征之间缺乏关联。
Leukemia. 2006 Jun;20(6):1165. doi: 10.1038/sj.leu.2404196.
4
[Myeloproliferative diseases caused by JAK2 mutation].由JAK2突变引起的骨髓增殖性疾病
Rinsho Byori. 2009 Apr;57(4):357-64.
5
[Molecular mechanisms in myeloproliferative diseases and myelodysplastic syndromes].骨髓增殖性疾病和骨髓增生异常综合征的分子机制
Nihon Rinsho. 2009 Oct;67(10):1901-5.
6
Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis.伴有纤维化的发育异常性骨髓疾病（MDS 和 CMML I）中原始细胞计数对预后的影响。
Ann Hematol. 2014 Jan;93(1):57-64. doi: 10.1007/s00277-013-1945-4. Epub 2013 Nov 17.
7
The JAK2 V617F mutation is rare in RARS but common in RARS-T.JAK2 V617F突变在RARS中罕见，但在RARS-T中常见。
Leukemia. 2006 Nov;20(11):2060-1. doi: 10.1038/sj.leu.2404373. Epub 2006 Aug 24.
8
JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.JAK2（V617F）等位基因负荷可将原发性血小板增多症与一部分纤维化前期原发性骨髓纤维化区分开来。
Exp Hematol. 2009 Oct;37(10):1186-1193.e7. doi: 10.1016/j.exphem.2009.07.005. Epub 2009 Jul 17.
9
Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.JAK2时代慢性骨髓增殖性疾病的组织学和分子分类：尽管有了新答案，但老问题依然存在。
Pathobiology. 2007;74(2):72-80. doi: 10.1159/000099120.
10
The emergence of a JAK2 V617F-mutated clone in myelodysplastic syndrome is associated with disease progression and features of myelofibrosis.骨髓增生异常综合征中JAK2 V617F突变克隆的出现与疾病进展及骨髓纤维化特征相关。
Br J Haematol. 2019 Aug;186(3):396. doi: 10.1111/bjh.15984. Epub 2019 May 28.
Zotero 插件